Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Financing Activities (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Cash from Financing Activities readings, the most recent being $37.3 million for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 112.86% to $37.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$38.3 million, a 92.13% increase, with the full-year FY2025 number at -$38.3 million, up 92.13% from a year prior.
  • Cash from Financing Activities hit $37.3 million in Q4 2025 for Neurocrine Biosciences, down from $45.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $69.9 million in Q1 2024 to a low of -$293.0 million in Q2 2024.
  • Median Cash from Financing Activities over the past 5 years was $7.8 million (2023), compared with a mean of -$33.3 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 1266.67% in 2022 and later tumbled 10203.45% in 2024.
  • Neurocrine Biosciences' Cash from Financing Activities stood at $1.8 million in 2021, then soared by 1266.67% to $24.6 million in 2022, then surged by 43.9% to $35.4 million in 2023, then tumbled by 919.21% to -$290.0 million in 2024, then skyrocketed by 112.86% to $37.3 million in 2025.
  • The last three reported values for Cash from Financing Activities were $37.3 million (Q4 2025), $45.6 million (Q3 2025), and -$3.3 million (Q2 2025) per Business Quant data.